A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to...

per Zimovetz, Evelina A., Beard, Stephen M., Hodgkins, Paul, Bischof, Matthias, Mauskopf, Josephine A., Setyawan, Juliana
Publicat a CNS Drugs (2016)

A review of health utilities across conditions common in paediatric and adult populations

per Tarride, Jean-Eric, Burke, Natasha, Bischof, Matthias, Hopkins, Robert B, Goeree, Linda, Campbell, Kaitryn, Xie, Feng, O'Reilly, Daria, Goeree, Ron
Publicat 2010

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and...

per Dean, Rebecca, Jensen, Ivar, Cyr, Phil, Miller, Beckley, Maru, Benit, Sproule, Douglas M., Feltner, Douglas E., Wiesner, Thomas, Malone, Daniel C., Bischof, Matthias, Toro, Walter, Dabbous, Omar
Publicat a J Mark Access Health Policy (2021)

Preferential accumulation within tumors and in vivo imaging by functionalized luminescent dendrimer lanthanide complexes

per Alcala, Marco A., Shade, Chad M., Uh, Hyounsoo, Kwan, Shu Ying, Bischof, Matthias, Thompson, Zachary P., Gogick, Kristy A., Meier, Adam R., Strein, Timothy G., Bartlett, David L., Modzelewski, Ruth A., Lee, Yong J., Petoud, Stéphane, Brown, Charles Komen
Publicat 2011